NASDAQ:IPCI - IntelliPharmaCeutics Intl Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.26 +0.01 (+4.02 %) (As of 05/19/2019 04:00 PM ET)Previous Close$0.2590Today's Range$0.2580 - $0.284052-Week Range$0.20 - $6.60Volume81,653 shsAverage Volume1.02 million shsMarket Capitalization$5.68 millionP/E RatioN/ADividend YieldN/ABeta2.17 ProfileAnalyst RatingsChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email IntelliPharmaCeutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Oxycodone ER, an abuse deterrent oxycodone hydrochloride extended release tablets; Regabatin and Lyrica pregabalin extended-release capsules for the management of neuropathic pain; Effexor XR, an extended-release capsule for oral administration to treat depression; Protonix, a delayed-release capsule for oral administration to treat gastroesophageal reflux disease; and Glucophage XR, a drug that treats type 2 diabetes. It also provides Seroquel XR, an oral psychotropic agent for the treatment of schizophrenia, bipolar disorder, and major depressive disorder; Lamictal XR, an anticonvulsant drug to terat epilepsy; Keppra XR, an antiepileptic drug for the treatment of partial onset seizures in patients with epilepsy; Pristiq, a selective serotonin and norepinephrine reuptake inhibitor to treat major depressive disorder; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company provides Focalin XR, an extended-release capsule for hyperactivity disorder. It has has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada. Receive IPCI News and Ratings via Email Sign-up to receive the latest news and ratings for IPCI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IPCI Previous Symbol CUSIPN/A CIK1474835 Webwww.intellipharmaceutics.com Phone416-798-3001Debt Debt-to-Equity RatioN/A Current Ratio1.64 Quick Ratio1.59Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.71 million Price / Sales3.32 Cash FlowN/A Price / Cash FlowN/A Book Value$0.43 per share Price / Book0.60Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-13,750,000.00 Net Margins-802.10% Return on EquityN/A Return on Assets-233.28%Miscellaneous EmployeesN/A Outstanding Shares21,930,000Market Cap$5.68 million Next Earnings DateN/A OptionableOptionable IntelliPharmaCeutics Intl (NASDAQ:IPCI) Frequently Asked Questions What is IntelliPharmaCeutics Intl's stock symbol? IntelliPharmaCeutics Intl trades on the NASDAQ under the ticker symbol "IPCI." When did IntelliPharmaCeutics Intl's stock split? How did IntelliPharmaCeutics Intl's stock split work? IntelliPharmaCeutics Intl shares reverse split on Friday, September 14th 2018. The 1-10 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 13th 2018. An investor that had 100 shares of IntelliPharmaCeutics Intl stock prior to the reverse split would have 10 shares after the split. How were IntelliPharmaCeutics Intl's earnings last quarter? IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) issued its quarterly earnings results on Monday, July, 16th. The company reported ($0.70) earnings per share for the quarter, meeting the Zacks' consensus estimate of ($0.70). The business had revenue of $0.58 million for the quarter, compared to analysts' expectations of $0.90 million. View IntelliPharmaCeutics Intl's Earnings History. What price target have analysts set for IPCI? 2 brokers have issued twelve-month price targets for IntelliPharmaCeutics Intl's shares. Their predictions range from $6.00 to $30.00. On average, they expect IntelliPharmaCeutics Intl's share price to reach $18.00 in the next year. This suggests a possible upside of 6,849.8% from the stock's current price. View Analyst Price Targets for IntelliPharmaCeutics Intl. What is the consensus analysts' recommendation for IntelliPharmaCeutics Intl? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IntelliPharmaCeutics Intl in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IntelliPharmaCeutics Intl. Has IntelliPharmaCeutics Intl been receiving favorable news coverage? Headlines about IPCI stock have trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. IntelliPharmaCeutics Intl earned a news sentiment score of 1.8 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 8.0 out of 10, indicating that recent news coverage is very likely to have an impact on the stock's share price in the near term. Who are some of IntelliPharmaCeutics Intl's key competitors? Some companies that are related to IntelliPharmaCeutics Intl include Novelion Therapeutics (NVLN), SUMMIT THERAPEU/S (SMMT), Onconova Therapeutics (ONTX), Jaguar Health (JAGX), BENITEC BIOPHAR/S (BNTC), Novus Therapeutics (NVUS), Provectus Biopharmaceuticals (PVCT), Fibrocell Science (FCSC), Cassava Sciences (SAVA), Pain Therapeutics (PTIE), Aileron Therapeutics (ALRN), IMMURON LTD/S (IMRN), Advaxis (ADXS), KITOV PHARMA LT/S (KTOV) and Gemphire Therapeutics (GEMP). What other stocks do shareholders of IntelliPharmaCeutics Intl own? Based on aggregate information from My MarketBeat watchlists, some companies that other IntelliPharmaCeutics Intl investors own include Brainstorm Cell Therapeutics (BCLI), Eyepoint Pharmaceuticals (EYPT), Biocept (BIOC), Progenics Pharmaceuticals (PGNX), Synergy Pharmaceuticals (SGYP), CytRx (CYTR), Geron (GERN), Inovio Pharmaceuticals (INO), OpGen (OPGN) and SCYNEXIS (SCYX). Who are IntelliPharmaCeutics Intl's key executives? IntelliPharmaCeutics Intl's management team includes the folowing people: Dr. Isa Odidi, Co-Founder, Chairman, CEO & Co-Chief Scientific Officer (Age 61)Dr. Amina Odidi, Pres, COO, Co-Chief Scientist Officer & Director (Age 59)Mr. Greg Powell, Chief Financial Officer How do I buy shares of IntelliPharmaCeutics Intl? Shares of IPCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is IntelliPharmaCeutics Intl's stock price today? One share of IPCI stock can currently be purchased for approximately $0.2590. How big of a company is IntelliPharmaCeutics Intl? IntelliPharmaCeutics Intl has a market capitalization of $5.68 million and generates $1.71 million in revenue each year. What is IntelliPharmaCeutics Intl's official website? The official website for IntelliPharmaCeutics Intl is http://www.intellipharmaceutics.com. How can I contact IntelliPharmaCeutics Intl? IntelliPharmaCeutics Intl's mailing address is 30 WORCESTER ROAD, TORONTO A6, M9W 5X2. The company can be reached via phone at 416-798-3001 or via email at [email protected] MarketBeat Community Rating for IntelliPharmaCeutics Intl (NASDAQ IPCI)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 291 (Vote Outperform)Underperform Votes: 209 (Vote Underperform)Total Votes: 500MarketBeat's community ratings are surveys of what our community members think about IntelliPharmaCeutics Intl and other stocks. Vote "Outperform" if you believe IPCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPCI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: The Role of a Fiduciary and Individual Investors Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.